AMLX Q4 2022 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M

Gross Profit

$19M87.1% margin

Operating Income

-$45M-203.8% margin

Net Income

-$43M-195.1% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

+6243.5%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$391M

Total Liabilities

$51M

Stockholders' Equity

$341M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$0	—
Gross Profit	$19M	$0	—
Operating Income	-$45M	-$28M	-57.5%
Net Income	-$43M	-$28M	-50.7%